purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation mnkd earnings call period ending march image source motley fool mannkind mnkd q earnings callmay pm etcontents prepared remark question answer call participant prepared remark operatorgood afternoon welcome mannkind corporation first quarter financial result earnings call reminder call recorded may th available playback mannkind corporation website shortly conclusion call may nd call contain forwardlooking statement forwardlooking statement subject risk uncertainty cause actual risk differ materially stated expectation information company risk factor please see q report filed security exchange commission afternoon earnings release slide prepared presentation joining u today mannkind chief executive officer michael castagna evp former chief financial officer stephen binder chief financial officer chris prentiss would like turn conference mr castagna please go ahead sirmichael castagna chief executive officer good evening everyone welcome th earnings call thrilled report another exceptional quarter growth mannkind past eight quarter revenue surged testament dedication innovation team put u run rate million revenue made tremendous progress field inhaled insulin believe continue growth driver year come also excited share progress addressing rare orphan lung disease today thank joining u journey growth societal impact around world remind everyone mission mannkind give people control health freedom live lifewhen think translates product make meaningful impact patient every single day look q record tyvaso dpi revenue almost million due strong sale united therapeutic record production q continue scale expansion facility building last several year number two mnkd made several strategic advancement ind cleared fast track designation well setup meet japanese authority get clearance expect pursue japanese registration approval road also activate clinical trial site second half also received green light proceed phase expect start momentarily diabetes business thing going nicely given upset change healthcare look april growing volume year year believe challenge happened q behind u look q going forward provide comment get discussion today financials steve go great detail want say thank work team done ended q million cash million previous quarter gaap net income million continue reduce leverage came q mnkd clofazimine inhalation suspension moving promising area think nebulizer version next deck product developed key part ntm treatment worldwide look ntm prevalence continuing grow unmet need exists around world believe billion opportunity two player coming year patient suffering greatly gearing hopefully bring new solution see chart unmet need really focus yous japan clinical trial site roughly share icon phase study design investigative launch meeting next month really talk study design expectation trial interest growing already site identified currently gearing contracting process hope enroll first patient end q aligned fda coprimary endpoint phase progressing want remind everybody year exclusivity orphan qidp designation look forward next pipeline ipf cough fibrotic disease could also looking ppf pulmonaryrelated condition look continued become unmet need two product approved littered failure difficult disease treat harmonize type patient studying look ofev done billion billion believe exciting opportunity reason excited look slide believe strongly product compete evolving landscape excited moving inhaled version could potentially reduce side effect see oral ofev maybe dose higher lung currently get product available believe rat pd bleomycin study first indicator dos identifying meet need patient published data yet internal data continue look way triangulate best chance success inhaled version day tox completed chronic tox done time roughly getting phase data looking forward moving forward human next month going focus endocrine business unit endocrine business grew year year strength afrezza look see growth afrezza offset decline vgo look vgo reduced sale force support dedicated vgo july last year january year transformed sale force footprint added resource toward afrezza directly impacted vgo doubled effort get ready grow afrezza faster key thing year start see fruit labor q field restructuring added field reimbursement team additional training support key account manager gearing support medical get ready release inhale followed inhale believe q already starting show benefit focus month april year year continue watch trend closely close q really excited new data afrezza could impact growth trajectory inhale remind type study went headtohead standard care whether mdi aid pump utilizing new conversion dose upfront presented data attd also another meal tolerance test followed baseline followed week presented yet goal equal efficacy standard care includes aid reason important doctor perceive best thing patient think going critical really understand data get ready launch want update conversion figure make decision whether separately together peds data based fda feedback get later year also remind second data readout later year week data provide interesting insight look patient got week continued additional week well remaining cohort patient switch switched first time doctor data experience around titration dosing hopefully continue see progress people switch second round versus first round inhale pediatric study focused yous one almost center expect secure pediatric approval beyond depend file six month month data let remind growth opportunity afrezza look coming decade first know type continue dominated glps double effort type diabetes inhale started last year data coming believe set u continued success type diabetes go headtohead competition look future child inhale critical milestone pivot point always said diabetes innovation started child whether cgm original insulin pump outman developed finally gestational diabetes getting lot attention day lot good reason believe support around alfreza continue grow interest guideline get updated data get generated longterm strategic initiative afrezza control outside control said going turn steve binder walk u financials steve binder executive vice president former chief financial officer thanks mike good afternoon pleased review select first quarter financial result please supplement call reading condensed consolidated financial statement mda contained q filed sec afternoon first quarter extended streak exceptional quarterly revenue growth total revenue growing versus first quarter eighth consecutive period quarteronquarter revenue growth let u start top table tyvaso dpi royalty generated million first quarter revenue growth q listened ut earnings call last week strong patient demand innovative product driving growth royalty based ut tyvaso dpi net revenue collaboration service revenue million increased versus first quarter mainly resulted higher level production activity higher volume semifinished tyvaso dpi unit sold ut higher average selling price per unit new source revenue targeting certain skus tyvaso dpi instead using third party sending ut kitting net revenue million grew versus first quarter primarily driven lower growth net percentage versus prior year price increase lower growth net percentage mainly result change estimate afrezza product return included first quarter afrezza result unfavorable impact net revenue due interruption copay card service change healthcare cyber intrusion february completely interrupted copay support well severely impacted ability pharmacy fulfill prescription copay program approximately two week vgo dropped million first quarter mainly driven lower demand resulting transitioning focus volume growth focus profitability vgo next slide show revenue growth source basic earnings per share quarterbyquarter basis rolling eightquarter period second quarter first quarter first quarter far righthand bar total revenue million increased sequentially versus fourth quarter versus second quarter first quarter tyvaso dpi commercial sale ut exceptional revenue growth dropping bottom line see graph show quarterly basic earnings loss per share first quarter third straight quarter net income positive earnings per share million net income share significant increase third fourth quarter moving gaap nongaap reconciliation gaap net income million adjusted select noncash item sole portion royalty revenue interest expense liability sale future royalty stock compensation gain loss foreign currency transaction related insulin purchase commitment produced nongaap net income million versus first quarter nongaap net loss million million quarterly yearonyear improvement fourth quarter earnings call laid plan deploying million cash investment balance sheet end highest priority slide update discussed year end priority changed since call begun execute plan see comment highlighted green fast track designation fda clearance move forward phase clinical trial mnkd fda clearance move forward phase clinical trial mnkd invest behind trial see executed quickly efficiently possible look opportunity grow afrezza faster new commercial model upcoming data readout intend wait see result inhale inhale making decision whether increase investment behind afrezza moving change debt structure executed early april first paid midcap senior secured debt freed u encumbrance asset discharged associated debt covenant eliminating highercost debt interest rate extinguished convertible debt without man trust converting part debt million share contractual conversion rate paid cash remaining outstanding debt paying cash reduced expected dilution two million share backing convertible debt also believe pershare price paid cash bargain company see price stock range severely undervalued continue evaluate senior convertible debt get closer march maturity intend best interest shareholder summarize grew total revenue year year another exceptional quarter revenue growth achieved eighth consecutive quarter revenue growth u run rate million annual revenue recorded million net income third consecutive quarter net income growing revenue used fund capital allocation priority favorably impacted ability grow net income earnings per share ended quarter million cash investment balance sheet started quarter without needing sell stock raise debt enter bd deal first sevenyear tenure mannkind last earnings call would like thank mike extended mannkind team mannkind board shareholder supported u dark day continued existence question support allowed executive team execute strategy build mannkind company bright future one proud thank turn back mikemichael castagna chief executive officer thank steve see upswing revenue trajectory continues strong continued shot goal increasing leverage infrastructure coming year let officially welcome chris say big thank steve could gotten done without steve thank everything done chris give second welcome mannkindchris prentiss chief financial officer thanks mike steve highlighted reviewing quarterly performance incredibly exciting time join mannkind may notice background actually returning mannkind began biotech career nearly two decade ago company knew year ago undergone remarkable transformation growing revenue stream robust pipeline focused improving life people living diabetes orphan lung disease focus working team expand upon positive momentum propel company forward look forward engaging upcoming conferencemichael castagna chief executive officer thank chris welcome back mannkindchris prentiss chief financial officer look pretty much hit milestone laid far q track hit milestone laid q really excited year second half one thing talk potential approval india clinical review india submitting feedback requested expect market authorization happen potential approval end year launch potentially continue give update progress want let know public knowledge point look anticipated key value driver mnkd underway mnkd proceeded clear look ofev revenue billion tremendous opportunity help lot people around world tyvaso dpi updated every patient covered look roughly million million revenue continue look upside projection production ut term study reading could provide meaningful upside today well endocrine business believe pediatrics key know answer later year well combination inhale continued growth afrezza internationally look diabetes market continue see roughly twothirds sale outside yous insulin tremendous opportunity help people around world one pursued rapidly time believe need get data set coming year set u beyond look opportunity communicate shareholder three thing coming annual shareholder meeting next week via internet please submit question please vote share well mine last night scientific conference endocrine two endocrine meeting coming ada meeting end june cd meeting end midaugust lung disease one first time attending ntm patient conference followed american thoracic society san diego next two week scientific presence continued engagement key thought leader place rbc conference next week followed leerink boston july believe got another invite august another conference update shortly thanks everything look forward talking next week please bring question try answer best thank question answer operatorthank operator instruction first question come line gregory renza rbc capital market line openanish nikhanj rbc capital market analyst yes hi mike team anish greg congrats quarter thanks taking question wanted ask inhale maybe could remind u help u set expectation inhale readout ada june bar success potentially key takeaway readthroughs previously disclosed initial meal challenge result also real quick thematic question next collaboration uthr teton study opportunity ipf ppf thanks muchmichael castagna chief executive officer thank anish inahle make clear expectation people believe aid best standard care wanted able show went type diabetes people perceive best afrezza good whatever measure want look ac time range etc patient aid mdi switched everybody degludec allow u roughly people study half going standard care half going afrezza week anyone standard care switch everybody try afrezza second changer also interesting analysis see happens week continuous afrezza versus week get second switch first week lot good data meal challenge test think show use dosing logarithm recommend safe number one effective number two versus standard care show think eat first two hour food generally peaking clearing meal challenge test meant show first two hour really get better mealtime control want right think key know dose product control patient world doctor real world going interesting see trial result come really look like see data totality think make clear win good standard care term really looking put aid well mdi total analysis individual component anything else inhale talk collaboration ut think agreement signed year ago additional collaboration opportunity work done license etc could happen focused tyvaso year different idea example brought public sale imatinib would inlicensed ut stage got exclusivity platform ph could move forward without bringing chose defer think biggest thing time discussion really around tyvasa going big thing going move needle turned true look back time think really trying find next going meaningful clinically end day moving forward orphan disease outside ph think ability fund grow get revenue shareholder patient helpanish nikhanj rbc capital market analyst great thanks much look forward seeing next weekmichael castagna chief executive officer ok thank youoperatorthank one moment next question next question come line olivia brayer cantor fitzgerald line openunknown speaker hey gugen olivia congrats great earnings wanted ask ipf program move clinic guy thinking path forward mnkd considered potentially working partner considering much interest marketmichael castagna chief executive officer yes think would say thing gugen ipf obviously challenging disease lot reason lot failure working inhale detention program many year stage execution meaning feel pretty good dose confirm phase around tolerability moving patient getting result feel mean work clear winner help lot people deal achilles heel market leader think billion drug almost million week door revenue would much rather shareholder versus partner think disease need ton infrastructure already built meaning specialty support service pharmacy distribution wholesaler patient training thing like really scaling providing best quality service possible patient provider directionally planning ahead think financially afford make trial go forward think data going drive decision get come ex yous market think continue reassess term gothrough distributor partner think perspective yous continue progress independentlyunknown speaker awesome sound great thank youoperatorthank one moment next question next question come line steve lichtman oppenheimer company line opensteve lichtman oppenheimer company analyst thank evening guy chris congratulation steve great working guess wanted ask p trial afrezza next milestone mike mentioned potential filing six month versus month know sort direction goesmichael castagna chief executive officer yes look competitive benchmark meaning insulin approved six month data discussion fda would like month data term safety think real question anything see sixmonth mark inconsistent thousand patient studied afrezza really plan go ahead ask file submission say pretty much majority patient patient done time fda approve product see reason wait another six month file may disagree think data assuming safe tolerable get positive surprise may help argument get negative surprise help u want get debate fda timing versus let u get clinical trial result discussion found collaborative everything far really key would like go six data help u get chance would wait full reality handful patient going trickling along beyond month beyond sixmonth time point sorrysteve lichtman oppenheimer company analyst ok helpful steve collaboration line well ahead mentioned number variable piece maybe size different piece pointed contributed quarter guess importantly sort sustainable item look model next quarterssteve binder executive vice president former chief financial officer thanks steve think back last year talked increasing tyvaso dpi bulk production time mid last year look quarterly cns revenue third quarter fourth quarter first quarter year growing expect higher activity sale united therapeutic allows u recognize revenue also couple thing q may repeat one higher level inventory tyveza dpi year end lower level end q inventory sold q got recognize revenue also ppq testing fill finish line could recognize revenue also deferred revenue call back deferred million worth deferred revenue first couple year contract starting actually see come get recognized need get recognized end manufacturing contract million deferred revenue got recognized q start see every quarter going michael castagna chief executive officer steve add ppq see additional ppq billing year steve important validating spray dryer validating additional strength recurring answer question kitting also recurring new u year two thing recurring go forward next couple quarterssteve lichtman oppenheimer company analyst ok got thank guysoperatorthank one moment next question next question come line thomas smith leerink partner line openthomas smith leerink partner analyst hey guy good afternoon thanks taking question congrats strong quarter couple question guess first inhaled intended program mentioned plan fund phase study pending phase result comment think potential regulatory path ipf whether potential registration basis single pivotal study whether base case would need second study enable registration theremichael castagna chief executive officer would say early comment publicly thing see example single trial could required sense endpoint like ipf specifically question get extrapolation ppf example would fda say one indication could enough approval want one another small study think precedent personally look biosimilars well tyvaso dpi got ild pah biosimilars getting full label specific indication even though study one think lot tbd going end phase meeting fda ultimately going drive next phase discussion think going importantthomas smith leerink partner analyst got helpful afrezza development plan ongoing inhale inhale study also highlighted potential gestational diabetes wondering could elaborate opportunity whether think would need specific study better access populationmichael castagna chief executive officer yes happened people inhale study recall specifically study part center study apologize saw postmeal challenge result attd really sparked discussion wow trying really control postprandial sugar first minute keep sugar injectable insulin slow take minute start working way gestational person really bring sugar two hour take minute start working felt saw meal challenge result could really help change goal guideline trying implement go forward got discussion another two thing requested one contribute drug pk study show obviously gestational woman could inhale rate adult concern obviously would want get data help support population next thing large trial going would like u part something would fund something third party would funding would providing drug support part help support part market going ask going consider large pregnancy trial answer time rule forever think got get pk data see good enough happened really two drug treat patient metformin rapidacting insulin would love something week treatment roughly short time period work feedback discussion go well hopefully get internal work well make sure feel comfortable overall situation requeststhomas smith leerink partner analyst got make sense thanks taking question appreciate itoperatorthank showing question time would like turn back michael castagna ceo closing remarksmichael castagna chief executive officer want clarify one thing commented via email share count outstanding share gone profit quarter yet show fully diluted share count average share count really million versus million last year million really going much may thought retail side overall want say thank steve great quarter firing cylinder team working really hard behalf really help patient lot meeting coming at going patient advisory board physician advisory board investigator meeting think mannkinds reputation moving inhaled orphan lung space going dramatically improve year pretty much every quarter start hopefully update clofazimines progress gotten hard work say hard work trial getting point miracle hard get drug development fact able proceed phase see light get patient near future fast drug development could possibly go work hard get best financial position saw u deleverage company continue best shareholder make sure allocating capital prudent expense thank look forward seeing upcoming investor conference please go ahead make sure ask question next week always want make sure open dialogue shareholder lot share exciting future looking forward continuing hopefully great performance coming year thank youoperatoroperator signoff duration minutescall participantsmichael castagna chief executive officersteve binder executive vice president former chief financial officerchris prentiss chief financial officeranish nikhanj rbc capital market analystunknown speakersteve lichtman oppenheimer company analystthomas smith leerink partner analyst mnkd analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy